Identification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting

Assay and Drug Development Technologies

Volumn 8, Issue 6, 2010, Pages 727-742

  Huang, Xi Ping ^a   Mangano, Thomas ^a   Hufeisen, Sandy ^a   Setola, Vincent ^a   Roth, Bryan L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; 8,9 DICHLORO 2,3,4,4A TETRAHYDRO 1H PYRAZINO[1,2 A]QUINOXALIN 5(6H) ONE; AMANTADINE; AMIODARONE; AMITRIPTYLINE; ARIPIPRAZOLE; BEPRIDIL; CHLORPHENIRAMINE; CHLORPROMAZINE; CICLOPIROX; CISAPRIDE; CLOMIPRAMINE; CLOZAPINE; CLOZAPINE N OXIDE; DOFETILIDE; DOXEPIN; DROPERIDOL; FLUOXETINE; FLUVOXAMINE; GREPAFLOXACIN; HALOPERIDOL; IMIPRAMINE; LIDOFLAZINE; LORATADINE; MAPROTILINE; MEFLOQUINE; MIBEFRADIL; NORTRIPTYLINE; OLANZAPINE; PD 118057; POTASSIUM CHANNEL HERG; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BINDING AFFINITY; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG POTENCY; DRUG SCREENING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENETIC SCREENING; PATCH CLAMP; POTASSIUM CURRENT; PROTEIN EXPRESSION; QT PROLONGATION; RAPID DELAYED RECTIFIER POTASSIUM CURRENT;

DRUG DISCOVERY; ETHER-A-GO-GO POTASSIUM CHANNELS; HEK293 CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; RADIOLIGAND ASSAY; THALLIUM;

EID: 78650441804     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2010.0331     Document Type: Article

References (56)

1. Warmke JW, Ganetzky B: A family of potassium channel genes related to eag in Drosophila and mammals. Proc Natl Acad Sci USA 1994;91:3438-3442.
2. Recanatini M, Poluzzi E, Masetti M, Cavalli A, De Ponti F: QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development. Med Res Rev, 2005;25:133-166.
3. Wible BA, Hawryluk P, Ficker E, KuryshevYA, Kirsch G, Brown AM: HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk. J Pharmacol Toxicol Methods 2005;52:136-145.
4. Kuryshev YA, Ficker E, Wang L, Hawryluk P, Dennis AT, Wible BA, Brown AM, Kang J, Chen XL, Sawamura K, Reynolds W, Rampe D: Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther 2005;312:316-323.
5. Rajamani S, Eckhardt LL, Valdivia CR, Klemens CA, Gillman BM, Anderson CL, Holzem KM, Delisle BP, Anson BD, Makielski JC, January CT: Drug-induced long QT syndrome: hERG K + channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol 2006;149:481-489.
6. Perrin MJ, Subbiah RN, Vandenberg JI, Hill AP: Human ether-a-go-go related gene (hERG) K + channels: function and dysfunction. Prog Biophys Mol Biol 2008;98:137-148.
7. Roden DM: Cellular basis of drug-induced torsades de points. Br J Pharmacol 2008;154:1502-1507.
8. Dennis A, Wang L, Wan X, Ficker E: hERG channel trafficking: novel targets in drug-induced long QT syndrome. Biochem Soc Trans 2007;35:1060-1063.
9. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT: A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995;80:795-803.
10. Sanguinetti MC, Tristani-Firouzi M: hERG potassium channels and cardiac arrhythmia. Nature 2006;440:463-469.
11. Brugada R, Hong K, Cordeiro JM, Dumaine R: Short QT syndrome. CMAJ 2005; 173:1349-1354.
12. Shah RR: Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives. Br J Pharmacol 2010;159:58-69.
13. Piccini JP, Whellan DJ, Berridge BR, Finkle JK, Pettit SD, Stockbridge N, Valentin JP, Vargas HM, Krucoff MW: Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative. Am Heart J 2009;158:317-326.
14. Shah RR: Can pharmacogenetics help rescue drugs withdrawn from the market? Pharmacogenomics 2006;7:889-908.
15. Netzer R, Bischoff U, Ebneth A: HTS techniques to investigate the potential effects of compounds on cardiac ion channels at early-stages of drug discovery. Curr Opin Drug Discov Dev 2003;6:462-469.
16. Fermini B, Fossa AA: The impact of drug-induced QT interval prolongation on drug discovery and development. Nat Rev Drug Discov 2003;2:439-447.
17. Finlayson K, Pennington AJ, Kelly JS: [3H]dofetilide binding in SHSY5Y and HEK293 cells expressing a HERG-like K + channel? Eur J Pharmacol 2001; 412:203-212.
18. Diaz GJ, Daniell K, Leitza ST, Martin RL, Su Z, McDermottJS, Cox BF, Gintant GA: The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: comparison of intact cell and membrane preparations and effects of altering K + o. J Pharmacol Toxicol Methods 2004;50:187-199.
19. Chiu PJ, Marcoe KF, Bounds SE, Lin CH, Feng JJ, Lin A, Cheng FC, Crumb WJ, Mitchell R: Validation of a [3H]-astemizole binding assay in HEK293 cells expressing HERG K + channels. J Pharmacol Sci 2004;95:311-319.
20. Cheng CS, Alderman D, Kwash J, Dessaint J, Patel R, Lescoe MK, Kinrade MB, Yu W: A high-throughput HERG potassium channel function assay: an old assay with a new look. Drug Dev Ind Pharm 2002;28:177-191.
21. Baxter DF, Kirk M, Garcia AF, Raimondi A, Holmqvist MH, Flint KK, Bojanic D, Distefano PS, Curtis R, Xie Y: A novel membrane potential-sensitive fluorescent dye improves cell-based assays for ion channels. J Biomol Screen 2002;7:79-85.
22. Falconer M, Smith F, Surah-Narwal S, Congrave G, Liu Z, Hayter P, Ciaramella G, Keighley W, Haddock P, Waldron G, Sewing A: High-throughput screening for ion channel modulators. J Biomed Screen 2002;7:460-465.
23. Titus SA, Beacham D, Shahane SA, Southall N, Xia M, Huang R, Hooten E, Zhao Y, Shou L, Austin CP, Zheng W: A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel. Anal Biochem 2009;394:30-38.
24. Beacham DW, Blackmer T, O'Grady M, Hanson GT: Cell-based potassium ion channel screening using the FluxOR assay. J Biomol Screen 2010;15:441-446.
25. Wang L, Wible BA, Wan X, Ficker E: Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking. J Pharmacol Exp Ther 2007;320:525-534.
26. Zhou J, Augelli-Szafran CE, Bradley JA, Chen X, Koci BJ, Volberg WA, Sun Z, Cordes JS: Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity. Mol Pharmacol 2005;68:876-884.
27. Armbruster BN, Li X, Pausch MH, Herlitze S, Roth RL: Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc Natl Acad Sci USA 2007;104:5163-5168.
28. Zeng H, Penniman JR, Kinose F, Kim D, Trepakova ES, Malik MG, Dech SJ, Balasubramanian B, Salata JJ: Improved throughput of PatchXpress hERG assay using intracellular potassium fluoride. Assay Drug Dev Technol 2008;6:235-241.
29. Cheng Y, Prusoff WH: Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973;22:3099-3108.
30. Polak S, Wisniowska B, Brandys J: Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties. J Appl Toxicol 2009;29:183-206.
31. Cordes JS, Sun Z, Lloyd DB, Bradley JA, Opsahl AC, Tengowski MW, Chen X, Zhou J: Pentamidine reduces hERG expression to prolong the QT interval. Br J Pharmacol 2005;145:15-23.
32. Schwartz M, Patel M, Kazzi Z, Morgan B: Cardiotoxicity after massive amantadine overdose. J Med Toxicol 2008;4:173-179.
33. Fossa AA, Gorczyca W, Wisialowski T, Yasgar A, Wang E, Crimin K, Volberg W, Zhou J: Electrical alternans and hemodynamics in the anesthetized guinea pig can discriminate the cardiac safety of antidepressants. J Pharmacol Toxicol Methods 2007;55:78-85.
34. Danielsson BR, Lansdell K, Patmore L, Tomson T: Phenytoin and phenobarbital inhibit human HERG potassium channels. Epilepsy Res 2003;55:147-157.
35. Nobile M,Vercellino P: Inhibition of delayed rectifier K + channels by phenytoin in rat neuroblastoma cells. Br J Pharmacol 1997;120:647-652.
36. Milnes JT, Dempsey CE, Ridley JM, Crociani O, Arcangeli A, Hancox JC, Witchel HJ: Preferential closed channel blockade of HERG potassium currents by chemically synthesised BeKm-1 scorpion toxin. FEBS Lett 2003;547:20-26.
37. Zhang M, Korolkova YV, Liu J, Jiang M, Grishin EV, Tseng GN: BeKm-1 is a HERG-specific toxin that shares the structure with ChTx but the mechanism of action with ErgTx1. Biophys J 2003;84:3022-3036.
38. Yao JA, Du X, Lu D, Baker RL, Daharsh E, Atterson P: Estimation of potency of HERG channel blockers: impact of voltage protocol and temperature. J Pharmacol Toxicol Methods 2005;52:146-153.
39. Bischoff U, Schmidt C, Netzer R, Pongs O: Effects of fluoroquinolones on HERG currents. Eur J Pharmacol 2000;406:341-343.
40. Kang J, Chen XL, Wang L, Rampe D: Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK and HERG. J Pharmacol Exp Ther 2001;299:290-296.
41. Lu HR, Vlaminckx E, Van de Water A, Rohrbacher J, Hermans A, Gallacher DJ: In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation. Eur J Pharmacol 2007;577:222-232.
42. Eberhard Y, McDermott SP, Wang X, Gronda M, Venugopal A, Wood TW, Hurren R, Datti A, Batey RA, Wrana J, Antholine WE, Dick JE, Schimmer AD: Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood 2009;114:3064-3073.
43. Hoque M, Hanauske-Abel HM, Palumbo P, Saxena D, D'Alliessi Gandolfi D, Park MH, Peery T, Mathews MB: Inhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A. Retrovirology 2009;6:90.
44. Dolderer JH, Schuldes H, Bockhorn H, Altmannsberger M, Lambers C, von Zabern D, Jonas D, Schwegler H, Linke R, Schroder UH: HERG1 gene expression as a specific tumor marker in colorectal tissues. Eur J Surg Oncol 2009;36: 72-77.
45. Ganapathi SB, Kester M, Elmslie KS: State-dependent block of HERG potassium channels by R-roscovitine: implications for cancer therapy. Am J Physiol Cell Physiol 2009;296:C701-C710.
46. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC: A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 2000;97:12329-12333.
47. Weaver CD, Harden D, DworetzkySI, Robertson B, Knox RJ: A thallium-sensitive, fluorescence-based assay for detecting and characterizing potassium channel modulators in mammalian cells. J Biomol Screen 2004;9:671-677.
48. Perry M, Sachse FB, Abbruzzese J, Sanguinetti MC: PD-118057 contacts the pore helix of hERG1 channels to attenuate inactivation and enhance K + conductance. Proc Natl Acad Sci USA 2009;106:20075-20080.
49. Kirsch GE, Trepakova ES, Brimecombe JC, Sidach SS, Erickson HD, Kochan MC, Shyjka LM, Lacerda AE, Brown AM: Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. J Pharmacol Toxicol Methods 2004;50:93-101.
50. Milnes JT, Witchel HJ, LeaneyJL, Leishman DJ, Hancox JC: Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: cisapride versus dofetilide. J Pharmacol Toxicol Methods 2010;61:178-191.
51. Ficker E, Dennis AT, Wang L, Brown AM: Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel HERG. Circ Res 2003;92:e87-e100.
52. Chen J, Sroubek J, Krishnan Y, Li Y, Bian J, McDonald TV: PKA phosphorylation of HERG protein regulates the rate of channel synthesis. Am J Physiol Heart Circ Physiol 2009;296:H1244-H1254.
53. Orlov SN, Thorin-Trescases N, Kotelevtsev SV, Tremblay J, Hamet P: Inversion of the intracellular Na + /K + ratio blocks apoptosis in vascular smooth muscle at a site upstream of caspase-3. J Biol Chem 1999;274:16545-16552.
54. Guo J, Massaeli H, Xu J, Jia Z, Wigle JT, Mesaeli N, Zhang S: Extracellular K + concentration controls cell surface density of IKr in rabbit hearts and of the HERG channel in human cell lines. J Clin Invest 2009;1 19:2745-2757.
55. Massaeli H, Guo J, Xu J, Zhang S: Extracellular K + is a prerequisite for the function and plasma membrane stability of HERG channels. Circ Res 2010;106:1072-1082.
56. Walker VE, Wong MJ, Atanasiu R, Hantouche C, Young JC, Shrier A: Hsp40 chaperones promote degradation of the HERG potassium channel. J Biol Chem 2010;285:3319-3329.